Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.1
2.4
Journals
Medicina
Special Issues
Diagnosis and Treatment of Cervical Cancer: Second Edition
share announcement

Diagnosis and Treatment of Cervical Cancer: Second Edition

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Obstetrics and Gynecology".

Deadline for manuscript submissions: closed (25 December 2025) | Viewed by 2054

Special Issue Editors

Dr. Tullio Golia D’Augè

E-Mail Website
Guest Editor
Department of Maternal and Child Health and Urological Sciences, Sapienza University of Rome, Policlinico Umberto I, 00161 Rome, Italy
Interests: gynecological oncology; endometrial cancer; gynecological surgery; ovarian cancer; cervical cancer
Special Issues, Collections and Topics in MDPI journals
Dr. Giorgia Perniola

E-Mail Website
Guest Editor
Department of Gynecological, Obstetrical and Urological Sciences, Sapienza University of Rome, 00161 Rome, Italy
Interests: gynecologic oncology; cervical cancer; endometrial cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cervical cancer remains a significant global health concern. While its incidence is declining in high-income countries, primarily thanks to healthier prevention strategies, HPV vaccination, and general screening, this malignancy continues to be a major burden in low- and middle-income countries. Persistent infection with high-risk human papillomavirus (HPV) types is recognized as the principal etiological factor. Screening using cytology (Pap test) and HPV-DNA testing permits the early diagnosis and treatment of cervical intraepithelial neoplasia (CIN), preventing the development of invasive cancer. However, disparities in access to screening and healthcare services continue to be a critical challenge.

High-grade CIN can be efficiently managed with conservative surgical treatment, but recurrence is still observed in a subgroup of patients. Invasive cervical cancer management requires a tailored approach based on disease FIGO stage, histological subtype, and patient characteristics. While minimally invasive radical hysterectomy has been adopted for early-stage disease, concerns about oncologic outcomes have led to ongoing debate and further research.

The second volume of this Special Issue aims to provide an updated overview of current evidence regarding cervical cancer diagnosis and treatment. We welcome original research, systematic reviews, and meta-analyses addressing surgical techniques, diagnostic strategies, preventive interventions, and future directions in this field. It is my pleasure to invite you to contribute to this Special Issue, entitled "Diagnosis and Treatment of Cervical Cancer: Second Edition". We published five papers in the first volume.

Dr. Tullio Golia D’Augè
Dr. Giorgia Perniola
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cervical cancer
  • radical hysterectomy
  • prevention
  • cervical intraepithelial neoplasia
  • cervical cancer screening
  • early diagnosis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

15 pages, 716 KB  
Article
Comprehensive Genomic Characterization of 102 Cervical Adenocarcinoma Tumors
by Gejla Toromani, Grace S. Saglimbeni, Bhanu Surabi Upadhyayula, Eugene Manu, Tyson J. Morris, Beau Hsia and Abubakar Tauseef
Medicina 2026, 62(1), 123; https://doi.org/10.3390/medicina62010123 - 7 Jan 2026
Viewed by 154
Abstract
Background and Objectives: Cervical adenocarcinoma (CAC) is a histologically distinct subtype of cervical cancer with a rising incidence in many regions. While the roles of key driver mutations are known, a comprehensive understanding of its genomic landscape, particularly variations across different populations and [...] Read more.
Background and Objectives: Cervical adenocarcinoma (CAC) is a histologically distinct subtype of cervical cancer with a rising incidence in many regions. While the roles of key driver mutations are known, a comprehensive understanding of its genomic landscape, particularly variations across different populations and tumor stages, remains incomplete. This study aims to characterize the somatic genomic landscape of CAC by identifying recurrent mutations, copy number alterations (CNAs), and patterns of co-occurrence, with a focus on variations across racial groups and between primary and metastatic tumors. Materials and Methods: We conducted a comprehensive genomic analysis of 102 tumor samples from 99 patients diagnosed with cervical adenocarcinoma using data from the American Association for Cancer Research (AACR) Project Genomics Evidence Neoplasia Information Exchange (GENIE) database. Results: The most frequently mutated genes were PIK3CA (25.5%), TP53 (21.6%), ARID1A (20.6%), and KRAS (16.7%). Significant amplification of ERBB2 was also observed (n = 3; 4.83%). Our analysis revealed notable genomic disparities across racial groups, with TP53 mutations being significantly more frequent in White patients compared to Asian and Black patients (p = 0.0236). Furthermore, we identified significant co-occurrence between mutations in KRAS and MSH2 (p = 0.011) as well as ATM and STK11 (p = 0.037). In comparing tumor types, mutations in BCL6 were found to be significantly enriched in metastatic samples. Conclusions: This study validates the primary drivers of cervical adenocarcinoma and reveals novel findings, including notable racial disparities in TP53 mutation frequency and unique patterns of co-occurring mutations. These findings highlight the genomic heterogeneity of the disease and suggest that ancestry and tumor evolution may influence its molecular pathogenesis, offering potential avenues for the development of targeted therapies and personalized biomarkers. Full article
(This article belongs to the Special Issue Diagnosis and Treatment of Cervical Cancer: Second Edition)
►▼ Show Figures

Figure 1

Review

Jump to: Research

21 pages, 764 KB  
Review
Sentinel Lymph Node Dissection—Novelty, Trend, or a Paradigm Shift in Surgical Decision-Making for Early Cervical Cancer?
by Angel Yordanov, Eva Tsoneva, Ihsan Hasan and Stoyan Kostov
Medicina 2025, 61(9), 1660; https://doi.org/10.3390/medicina61091660 - 12 Sep 2025
Viewed by 1604
Abstract
Cervical cancer remains the fourth most common malignancy among women worldwide, with over 600,000 new cases and approximately 350,000 deaths in 2022. Lymph node (LN) status is a critical prognostic factor, and in 2018, the International Federation of Gynecology and Obstetrics (FIGO) revised [...] Read more.
Cervical cancer remains the fourth most common malignancy among women worldwide, with over 600,000 new cases and approximately 350,000 deaths in 2022. Lymph node (LN) status is a critical prognostic factor, and in 2018, the International Federation of Gynecology and Obstetrics (FIGO) revised its staging system to include regional LN metastases, underscoring the importance of accurate nodal assessment. Sentinel lymph node biopsy (SLNB) has emerged as a minimally invasive alternative to systematic pelvic lymphadenectomy in early-stage disease, aiming to shorten operative time, reduce healthcare costs, and minimize treatment-related morbidity. This review synthesizes current evidence on SLNB in early-stage cervical cancer, including its diagnostic accuracy, optimal techniques, cost-effectiveness, and remaining clinical challenges. Data from prospective trials and meta-analyses demonstrate that SLNB provides high detection rates, especially with bilateral mapping and the use of advanced tracers such as indocyanine green. Ultrastaging further improves the detection of micrometastases and isolated tumor cells, refining adjuvant therapy decisions. Compared to full lymphadenectomy, SLNB significantly decreases intraoperative blood loss, operative time, and postoperative complications—most notably, lymphedema—while maintaining equivalent disease-free and overall survival. International guidelines now endorse SLNB for appropriately selected patients with early-stage cervical cancer (tumor size < 4 cm, negative preoperative imaging). However, variations persist between European and U.S. recommendations regarding its role as a standalone procedure. Future research must address protocol standardization, the prognostic relevance of low-volume metastases, and factors influencing mapping success. Overall, SLNB represents a paradigm shift toward more individualized, evidence-based surgical management of early-stage cervical cancer. Full article
(This article belongs to the Special Issue Diagnosis and Treatment of Cervical Cancer: Second Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop